Mavroudis [19] demonstrated the effective benefits of CSF levels of YKL-40 in the definition of AD and analyzed in detail its ability to be applied in combination with the other core biomarkers to assess the prognostic effect of MCI and its correlation with AD disease progression. This evidence concerns the gene CHI3L1 and Alzheimer disease.